A bispecific CD3×CD19 antibody for systemic lupus erythematosus: a phase 1 trial
Jason Xu, Chunli Mei, Xin Guan, Rong Du et autres
0 citationsNature Medicine
Michaela Liedtke
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
334Publications signalées
14515Citations signalées
7Affiliations récentes
Institutions déclarées
Domaines associés
Multiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, OutcomesAcute Lymphoblastic Leukemia researchCAR-T cell therapy researchAcute Myeloid Leukemia Research
Publications récentes
Pilot Study of Daratumumab for Reduction of Circulating Antibodies in Patients With High Allosensitization Awaiting Heart Transplantation
Ronald Witteles, Bing M. Zhang, Paul Cheng, Michaela Liedtke et autres
0 citationsJournal of Cardiac Failure
Safety and tolerability of anselamimab in participants with light chain amyloidosis: results from a phase 2 study
Jason Valent, Jeffrey A. Zonder, E. Scott Swenson, Julia Catini et autres
0 citationsEuropean Journal of Cancer
Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
Ashutosh D. Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, Efstathios Kastritis et autres
1 citationJournal of Clinical Oncology
POSTER: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
A. Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, Efstathios Kastritis et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
ORAL ABSTRACT: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
A. Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, Efstathios Kastritis et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
A. Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, Efstathios Kastritis et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
Ashutosh D. Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, Efstathios Kastritis et autres
1 citationJournal of Clinical Oncology
Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.
Ashutosh D. Wechalekar, Angela Dispenzieri, Vaishali Sanchorawala, E K Kastritis et autres
0 citationsJournal of Clinical Oncology
Long-term follow-up of a pediatric regimen for AYA with Ph-negative ALL: 10-year survival of CALGB 10403 (alliance)
Wellington Fernandes da Silva, Jun Yin, Michaela Liedtke, David Claxton et autres
1 citationBlood Advances
Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis
Efstathios Kastritis, Giovanni Palladini, Monique C. Minnema, Ashutosh D. Wechalekar et autres
2 citationsBlood
Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy
Masooma Rana, Sebastian Fernandez-Pol, Alexandria Jensen, Vanna Hovanky et autres
2 citationsBlood Cancer Journal
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.